Acute Porphyria Drugs

Acute Porphyria Drug Database

Monograph

N01BB10 - Levobupivacaine
Propably not porphyrinogenic
PNP
Rationale
The drug has not been found to induce or irreversible inhibit drug metabolizing cytochrome P450 species (Rendic, S., 2002) and is therefore most probably devoid of capacity for ALAS1-induction. Further, levobupivacaine is the S(-)-entiomer of the non-porphyrinogenic drug bupivacaine, and this gives theoretical grounds to classify levobupivacaine as probably not porphyrinogenic. One case of uneventful use reported.
Chemical description
Levobupivacaine is a local anesthetic of the amide type, the S(-)-entiomer of bupivacaine.
Therapeutic characteristics
Local anaesthtic. Levobupivacaine is equipotent to bupivacaine.
Hepatic exposure
Volume required to obtain uM concentrations when injected intravenously: approximately 4 ml (of levobupivacaine 5 mg/ml).
Metabolism and pharmacokinetics
The pharmacokinetics of levobupivacaine are similar to those of the racemic form, bupivacaine. It is extensively metabolised and excreted as its metabolites mainly in the urine, with smaller amounts appearing in the faeces. 3-Hydroxylevobupivacaine is a major metabolite and its formation is mediated by the cytochrome P450 isoenzyme CYP1A2; the isoenzyme CYP3A4 is also involved in the metabolism of levobupivacaine. Rendic (2002) reports that levobupivacaine is a substrate of CYP3A4 and CYP1A2. Gennery et al (2000) also concludes that metabolism is primarily via cytochrome P450 isoenzymes.
Personal communication
Thunell, S., study to be published: 1 patient exposed without porphyric adverse reaction reported.
IPNet drug reports
No.

References

# Citation details PMID
*Scientific articles
1. Gennery, B., Mather, L.E. et al. Levobupivacaine: New Preclinical and Clinical Data. Seminars in Anesthesia, Perioperative Medicine and Pain 2000;19 (2):132-148.
2. Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448.
3. Thunell, S. Evidence-based porphyrogenicity assessment of seven local anasthetics (2009, to be published).
*Drug reference publications
4. Sweetman SC, editor. Martindale: The complete drug reference. Levobupivacaine. Pharmaceutical Press 2009.
*Summary of Product Characteristics
5. Norwegian medicines agency. Summary of Product Characteristics (SPC). Chirocaine
Similar drugs
Explore alternative drugs in similar therapeutic classes N01B / N01BB or go back.
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia). Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway). What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.
Netherlands
Bupivacaïne · Bupivacaïne HCl Baxter 2,5 mg/ml oplossing voor injectie, oplossing voor injectie · Bupivacaïne HCl Baxter 5,0 mg/ml, oplossing voor injectie · Levobupivacaïne · Levobupivacaïne Fresenius Kabi 0,625 mg/ml, oplossing voor infusie · Levobupivacaïne Fresenius Kabi 1,25 mg/ml, oplossing voor infusie · Levobupivacaïne Fresenius Kabi 2,5 mg/ml, oplossing voor injectie/infusie · Levobupivacaïne Fresenius Kabi 5 mg/ml, oplossing voor injectie/infusie · Levobupivacaïne Fresenius Kabi 7,5 mg/ml, oplossing voor injectie/infusie · Levobupivacaïne Molteni 0,625 mg/ml, oplossing voor infusie · Levobupivacaïne Molteni 1,25 mg/ml, oplossing voor infusie · Levobupivacaïne Molteni 2,5 mg/ml, oplossing voor injectie/infusie · Levobupivacaïne Molteni 5 mg/ml, oplossing voor injectie/infusie · Levobupivacaïne Molteni 7,5 mg/ml, oplossing voor injectie/infusie
Belgium
Chirocaine · Chirocaine 1.25 mg/ml sol. perf. p.dural · Chirocaine 2.5 mg/ml sol. inj./perf. i.théc./i.derm./p.dural amp. · Chirocaine 5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Chirocaine 7.5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne · Levobupivacaïne Altan Pharma 0.625 mg/ml sol. perf. p.dural · Levobupivacaïne Altan Pharma 1.25 mg/ml sol. perf. p.dural · Levobupivacaïne Altan Pharma 2.5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne Altan Pharma 5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne Altan Pharma 7.5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne Fresenius Kabi 1.25 mg/ml sol. perf. p.dural · Levobupivacaïne Fresenius Kabi 2.5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne Fresenius Kabi 5 mg/ml sol. inj./perf. i.théc./p.dural amp. · Levobupivacaïne Fresenius Kabi 7.5 mg/ml sol. inj./perf. i.théc./p.dural amp.
United Kingdom
Chirocaine · Chirocaine 125mg/100ml infusion bags · Chirocaine 125mg/200ml infusion bags · Chirocaine 250mg/200ml infusion bags · Chirocaine 25mg/10ml solution for injection ampoules · Chirocaine 50mg/10ml solution for injection ampoules · Chirocaine 62.5mg/100ml infusion bags · Chirocaine 75mg/10ml solution for injection ampoules · Levobupivacaine · Levobupivacaine 125mg/100ml infusion bags · Levobupivacaine 125mg/200ml infusion bags · Levobupivacaine 250mg/200ml infusion bags · Levobupivacaine 25mg/10ml solution for injection ampoules · Levobupivacaine 50mg/10ml solution for injection ampoules · Levobupivacaine 62.5mg/100ml infusion bags · Levobupivacaine 75mg/10ml solution for injection ampoules
Poland
Levobupivacaine Molteni
Luxembourg
CHIROCAINE
Finland
Chirocaine
Serbia
Levobupivakain · Levobupivakain Kabi
 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙